CareDx (NASDAQ:CDNA) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Posted by Brian Himes on Jul 30th, 2026

CareDx (NASDAQ:CDNA – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.22 by $0.15, FiscalAI reports. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The company’s quarterly revenue was up 52.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share.

Here are the key takeaways from CareDx’s conference call:

Q2 revenue rose 52% to $132 million, while testing services revenue increased 61% to $100 million and adjusted EBITDA reached $25 million, or 19% of revenue. The company also ended the quarter with $374 million in cash and no debt.
CareDx raised its 2026 guidance to $490 million–$500 million in revenue and $66 million–$78 million in adjusted EBITDA, including $24 million of second-half specialty oncology revenue and 258,000–266,000 tests for the year.
Transplant testing growth remains strong, with Q2 volume up 17% to 58,000 tests as both surveillance and for-cause use expanded. Management cited broader clinical adoption, improved workflows, and evidence supporting AlloSure’s use in risk assessment and treatment monitoring.
The company reported progress across its growth pipeline and NavDx acquisition, including a planned 2027 AlloHeme commercial launch, a 2026 clinical-study launch for HistoMap Kidney, and integration initiatives intended to expand NavDx adoption and improve reimbursement and workflow efficiency.
Management characterized its outlook as prudent while it integrates NavDx billing and operating systems; specialty oncology is currently modeled at roughly 63% gross margin and may require additional investment, although CareDx continues to target approximately 20% long-term adjusted EBITDA margins.

CareDx Trading Up 7.6%

CDNA stock traded up $2.69 during midday trading on Thursday, hitting $38.10. 1,741,217 shares of the company’s stock were exchanged, compared to its average volume of 802,924. The business has a 50-day simple moving average of $28.15 and a two-hundred day simple moving average of $22.46. The stock has a market capitalization of $1.97 billion, a PE ratio of -238.12 and a beta of 2.43. CareDx has a 1-year low of $11.26 and a 1-year high of $40.47.

Insider Buying and Selling at CareDx

In other CareDx news, Director Hannah Valantine sold 12,103 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the completion of the transaction, the director owned 36,686 shares of the company’s stock, valued at $847,813.46. This trade represents a 24.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of CareDx stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the sale, the chief executive officer owned 661,959 shares of the company’s stock, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 78,936 shares of company stock worth $2,093,708. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of CareDx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in shares of CareDx by 1.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock worth $739,000 after buying an additional 711 shares during the period. The Manufacturers Life Insurance Company lifted its stake in CareDx by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock worth $542,000 after acquiring an additional 1,280 shares in the last quarter. Quarry LP acquired a new position in CareDx during the 4th quarter worth about $25,000. Franklin Resources Inc. boosted its holdings in CareDx by 3.8% during the 4th quarter. Franklin Resources Inc. now owns 103,703 shares of the company’s stock valued at $1,954,000 after acquiring an additional 3,774 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in CareDx by 120.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after acquiring an additional 4,160 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. Weiss Ratings downgraded shares of CareDx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, July 15th. Craig Hallum restated a “hold” rating and set a $35.00 price target on shares of CareDx in a research report on Thursday, July 16th. BTIG Research increased their price objective on shares of CareDx from $28.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, William Blair raised shares of CareDx to a “hold” rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $33.67.

Get Our Latest Stock Analysis on CareDx

About CareDx

(Get Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.